Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

Can't take credit for finding this as it is from another site.
The info is as up to date as possible and a great way of keeping up to date with developments re the CardioQ, as it's a pris of such developments.

www.reducinglengthofstay.org.

Hopefully this will get things moving at a fast pace.
If not I have the ideal Xmas gift for all NHS trust members.
A big box of suppositories as these might be the only thing to get them to move quickly.

Director Buys ( Late Nov07)
Frankly, for a Director to buy 10k's worth is laughable - I wonder if we will see some odd RNS slipped out with bad news?

This SP has returned to start-of-year values.. . . . . and I thought it was on the "up"
Wrong again!

Deltex Medical (DEMG-AIM) S.P. 23.25p.
Our share club has held a position with DEMG for some time now, on which we are showing a 5% profit.

. The Group's principal product is the CardioQ
which is used on patients undergoing surgery and on critically ill
patients to monitor the heart's performance. This provides disposable
ultra-sound probes inserted into the esophagus to determine the amount
of blood being pumped around the bodies circulating blood volume. The
CardioQ incorporates proprietary software and a small diameter,
minimally invasive, disposable esophageal probe that is used for
transmitting and receiving an ultra-sound signal. The Group operates in
the United Kingdom and the United States of America.

Why not follow the CardioQ story at our club website www.shareclubuk.co.uk. To find out more about .Deltex just click onto www.deltexmedical.com/.

Deltex Medical (DEMG-AIM) S.P. 23.25p. Market Cap 20.12m
Our share club has held a position with DEMG for some time now, on which we are showing a profit. Of 1.25%.

The main reason why we have invested in DEMG is the proven fact that the company lead product CardioQ is the number one product of its type in medical world, also that the company is opening up the U.S. market as CardioQ has been approved by the U.S. medical insurance board for insurance cover payments for patient, therefore opening up the market for DEMG.

Why not follow the CardioQ story at our club website www.shareclubuk.co.uk. To find out more about .Deltex just click onto www.deltexmedical.com/.

Yet another positive in the HSJ.
2517

Yes, yet another glowing report re the CardioQ. This time in The Health Service Journal (HSJ).
The article also states that the HSJ is widely read amongst NHS managers and the publication of Dr Webb's article shows the growing profile of our products in delivering solutions to the challenges facing modern NHS hospitals.

But I wonder if this cloth eared, wool for brains lot, who are not worth paying in sick bags can bl**dy well read.

They make me sicker than most NHS patients are on release.

Added a few more today @ this very low level, it's been a while since they were this price. Good luck all.
2517

I wonder how the NHS Technology Adoption Hub review is going, they have had 3 complete months now, maybe some feedback is due from them.
2517

Right on cue. Looks to be doing very well in all aspects, the only blip is SupraQ sales. Latin America becoming increasingly aware of DEMG's products.
2517

Significant progress in all of its key markets.
Anticipate that sales for the year will be in excess of 4.1 million.

Nice increase from 3,511,000 previous year. Outlook is looking very good, although
we are still it appears looking for that big breakthrough.
Be interesting to see if costs per item have decreased, as presumably with increase production they will have.
Still more patience needed, but a good pre close statement.
Looking forward to full results.

Deltex Medical (DEMG-AIM) S.P. 19.00p. Market Cap 20.12m
Our share club has held a position with DEMG for some time now, on which we are showing a profit. Of 1.15%. Hot news just in from DEMG

Positive scientific review of CardioQ technology published

Pre-close update on the year ended 31 December 2007

To find out more about .DEMG click onto www.deltexmedical.com/.

myway, previously you said (post 510) that at 23.25p you had a profit of 1.25% so you must have bought at 22.96p

Now you say that at 19.00p you have a profit of 1.15% so you must have bought at 18.78p

It is good to be in profit. I am hoping for a 400% profit at least.

Nice to see 3 directors buying, 70k in total.
2517

Thanks Art Dysg we are buying and selling as the markets trades

Deltex Medical (DEMG-AIM) S.P. 19.25p. Market Cap 20.12m

I was pleased to read the news last week that once more DEMG has a Positive scientific review of CardioQ technology published. CardioQ is the companys lead proven product

Marketing details from Pre-close update on the year ended 31 December 2007

"Deltex Medical continued to make significant progress during 2007 towards establishing the CardioQ as a global standard of care. We now have increasing momentum in the US and other key international markets as well as in the UK."

To find out more about .DEMG click onto www.deltexmedical.com/.

How depressing is this, the shares wavered around the same range for the last 4 years, you must all be buying low and waiting for the upwards spike selling and repeating yourselves....

Re the RNS.

Just how many more positive results re health and cost benefits must there be before the NHS take notice and positive action re this no brainer.
The RNS hasn't even moved the SP due to most feeling as if its the usual banging of heads of the proverbial brick wall.

Yet another trial result. BUT this one does not show how much the result was down to the laparoscopic surgery or the CardioQ, as the CardioQ was not used in the open surgery. So in reality it tells us nothing.
Still a big believe in the CardioQ but this does not imho enhance this believe.

The Company today announces that it has now made its first sale in connection with the NTAH.
Yet another update result, BUT this one is different.
IMHO as they now have a firm foothold re the NTAH, I feel this is finally the start of real progress in general use of the CardioQ.
I don't expect a sudden rush of further contracts, but I do expect from this release a far greater momentum in deals.

It has been mentioned on this thread several times that Private Hospitals in the UK, USA and other countries have no incentive to treat patients in such a manner as to procure their discharge earlier. The reasons stated for this are that the longer these patients stay in hospital the more money is made by these hospitals, both in length of stay charges and treatment costs as these are paid by either the patients themselves or insurance schemes.
With completion in the insurance industries that cover medical situations increasing at a fast pace, to me this augment is becoming a bit out dated.
There are an increasing number of patients going private in the UK (although this might obviously be reversed due to the credit squeeze) and as a result more medical facilities are offering private treatments.
Within a 20 mile radius of my home there are at least 3 different private medical hospitals offering a huge diversity of treatments. The private medical insurance I have has changed the hospital it uses 3 times in the last 10 years, presumably down to cost.
Surely if there is this amount of competition among both insurance companies and hospitals it must be beneficial to all that hospital stay times are as short as possible.
In countries that have their medical facilities mainly privately funded no doubt this incentive is even more in evidence.
I am obviously aware that the more these hospitals and insurance companies can charge and get away with they will do so, but if you look at other industries such as supermarkets, competition is the main leveler of low costs.
Get the CardioQ into your hospital, cut in patient times and get more customers makes sense to me.
All IMHO of course.

RNS.

First protocols for routine use of the CardioQ(TM) in intensive care established
at leading acute hospital in the USA.

This just has to be the spark that lights the CardioQ fire, surely.